

## ESPS PEER-REVIEW REPORT

**Name of journal:** World Journal of Gastroenterology

**ESPS manuscript NO:** 25884

**Title:** Immunotherapy in Human Colorectal Cancer: Challenges and Prospective

**Reviewer's code:** 00075352

**Reviewer's country:** Spain

**Science editor:** Ya-Juan Ma

**Date sent for review:** 2016-03-25 14:52

**Date reviewed:** 2016-03-28 19:37

CLASSIFICATION	LANGUAGE EVALUATION	SCIENTIFIC MISCONDUCT	CONCLUSION
<input checked="" type="checkbox"/> Grade A: Excellent	<input checked="" type="checkbox"/> Grade A: Priority publishing	Google Search:	<input type="checkbox"/> Accept
<input type="checkbox"/> Grade B: Very good	<input type="checkbox"/> Grade B: Minor language polishing	<input type="checkbox"/> The same title	<input type="checkbox"/> High priority for publication
<input type="checkbox"/> Grade C: Good	<input type="checkbox"/> Grade C: A great deal of language polishing	<input type="checkbox"/> Duplicate publication	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade D: Rejected	<input checked="" type="checkbox"/> No	<input checked="" type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E: Poor		BPG Search:	<input type="checkbox"/> Major revision
		<input type="checkbox"/> The same title	
		<input type="checkbox"/> Duplicate publication	
		<input type="checkbox"/> Plagiarism	
		<input checked="" type="checkbox"/> No	

## COMMENTS TO AUTHORS

The authors submit an interesting review regarding immunotherapy in Colorectal cancer; with thoughtful comments. The text is well written. In the introduction the authors confuse the treatment of colon cancer vs rectal cancer. They mentioned the neoadjuvant therapy which is accepted in locally advanced rectal cancer but not in colon cancer. They should correct this issue. In page 10, I am concerned with the statement regarding the benefit of OncoVax in stage II of colon cancer. These patients have an excellent prognosis despite 20% develop recurrence. The authors should discuss this issue.

## ESPS PEER-REVIEW REPORT

**Name of journal:** World Journal of Gastroenterology

**ESPS manuscript NO:** 25884

**Title:** Immunotherapy in Human Colorectal Cancer: Challenges and Prospective

**Reviewer's code:** 01844002

**Reviewer's country:** Japan

**Science editor:** Ya-Juan Ma

**Date sent for review:** 2016-03-25 14:52

**Date reviewed:** 2016-04-18 16:41

CLASSIFICATION	LANGUAGE EVALUATION	SCIENTIFIC MISCONDUCT	CONCLUSION
<input type="checkbox"/> Grade A: Excellent	<input checked="" type="checkbox"/> Grade A: Priority publishing	Google Search:	<input type="checkbox"/> Accept
<input type="checkbox"/> Grade B: Very good	<input type="checkbox"/> Grade B: Minor language polishing	<input type="checkbox"/> The same title	<input type="checkbox"/> High priority for publication
<input checked="" type="checkbox"/> Grade C: Good	<input type="checkbox"/> Grade C: A great deal of language polishing	<input type="checkbox"/> Duplicate publication	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade D: Rejected	<input checked="" type="checkbox"/> Plagiarism	<input checked="" type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E: Poor		[ Y ] No	<input type="checkbox"/> Major revision
		BPG Search:	
		<input type="checkbox"/> The same title	
		<input type="checkbox"/> Duplicate publication	
		<input type="checkbox"/> Plagiarism	
		<input checked="" type="checkbox"/> No	

## COMMENTS TO AUTHORS

In their manuscript Sun et al. provides timely and comprehensive but concise review on immunotherapy for colorectal cancer. Generally the manuscript is well written and conceivable. However, limitations in addition to the mechanistic insights and/or a rationale behind each of type of immunotherapy are hopefully described before it acceptance.

## ESPS PEER-REVIEW REPORT

**Name of journal:** World Journal of Gastroenterology

**ESPS manuscript NO:** 25884

**Title:** Immunotherapy in Human Colorectal Cancer: Challenges and Prospective

**Reviewer's code:** 03508891

**Reviewer's country:** Italy

**Science editor:** Ya-Juan Ma

**Date sent for review:** 2016-03-25 14:52

**Date reviewed:** 2016-04-24 17:00

CLASSIFICATION	LANGUAGE EVALUATION	SCIENTIFIC MISCONDUCT	CONCLUSION
<input type="checkbox"/> Grade A: Excellent	<input type="checkbox"/> Grade A: Priority publishing	Google Search:	<input type="checkbox"/> Accept
<input type="checkbox"/> Grade B: Very good	<input type="checkbox"/> Grade B: Minor language	<input type="checkbox"/> The same title	<input type="checkbox"/> High priority for
<input type="checkbox"/> Grade C: Good	polishing	<input type="checkbox"/> Duplicate publication	publication
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade C: A great deal of	<input type="checkbox"/> Plagiarism	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade E: Poor	language polishing	<input type="checkbox"/> No	<input type="checkbox"/> Minor revision
	<input type="checkbox"/> Grade D: Rejected	BPG Search:	<input type="checkbox"/> Major revision
		<input type="checkbox"/> The same title	
		<input type="checkbox"/> Duplicate publication	
		<input type="checkbox"/> Plagiarism	
		<input type="checkbox"/> No	

## COMMENTS TO AUTHORS

The paper by Sun et al provides a good review of the current scenario in CRC immunotherapy. Only some minimal changes are needed: -The author should take into account that neoadjuvant treatment with radio/chemotherapy is valid option only for rectal cancer and not for colon cancer. Please better clarify this part in the introduction, where it seems that these options are valid for all CRC cancer. - In the section dedicated to CRC immunotherapy, the author should include a sub-paragraph dedicated to chemoimmunotherapy, where Correale et al published different phase 1-2 (including a combination of chemoimmunotherapy and cancer vaccine) and a phase 3 trial in colorectal cancer.

## ESPS PEER-REVIEW REPORT

**Name of journal:** World Journal of Gastroenterology

**ESPS manuscript NO:** 25884

**Title:** Immunotherapy in Human Colorectal Cancer: Challenges and Prospective

**Reviewer's code:** 00227359

**Reviewer's country:** Turkey

**Science editor:** Ya-Juan Ma

**Date sent for review:** 2016-03-25 14:52

**Date reviewed:** 2016-04-25 02:00

CLASSIFICATION	LANGUAGE EVALUATION	SCIENTIFIC MISCONDUCT	CONCLUSION
<input type="checkbox"/> Grade A: Excellent	<input checked="" type="checkbox"/> Grade A: Priority publishing	Google Search:	<input type="checkbox"/> Accept
<input checked="" type="checkbox"/> Grade B: Very good	<input type="checkbox"/> Grade B: Minor language polishing	<input type="checkbox"/> The same title	<input checked="" type="checkbox"/> High priority for publication
<input type="checkbox"/> Grade C: Good	<input type="checkbox"/> Grade C: A great deal of language polishing	<input type="checkbox"/> Duplicate publication	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade D: Rejected	<input checked="" type="checkbox"/> Plagiarism	<input type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E: Poor		<input checked="" type="checkbox"/> No	<input type="checkbox"/> Major revision
		BPG Search:	
		<input type="checkbox"/> The same title	
		<input type="checkbox"/> Duplicate publication	
		<input type="checkbox"/> Plagiarism	
		<input checked="" type="checkbox"/> No	

## COMMENTS TO AUTHORS

As a surgeon I learnt lots of things about the promising medical treatments of the CRCs. It summed up the update trials on the topic.